Cytokinetics (CYTK) investor relations material

MYQORZO launch and early performance

• MYQORZO launched in late January with encouraging early signs and high awareness among targeted cardiologists, especially those familiar with CAMZYOS.

• Over 700 cardiologists have completed the REMS program, and prescriptions are being written by both experienced and new prescribers.

• Initial interest includes requests for information on switching patients from CAMZYOS, though switching is not seen as a primary growth driver.

• Differentiation is based on speed of onset, dosing flexibility, and a tailored physician and patient experience.

• Promotion strategy emphasizes safety, efficacy, and streamlined reimbursement processes.

Financial strategy and global expansion

• Investments were made to strengthen the balance sheet ahead of U.S. and European launches, including a partnership with Royalty Pharma and a convertible notes offering.

• MYQORZO is approved in Europe, with a Q2 launch planned in Germany, and partners are preparing launches in China and Japan.

• European investment is staged and gated to reimbursement milestones, learning from experiences in key markets.

• Capital allocation prioritizes U.S. and European launches and ongoing pipeline development.

ACACIA-HCM trial and pipeline outlook

• ACACIA-HCM is designed to test MYQORZO in non-obstructive HCM, a population similar in size to obstructive HCM but with no approved treatments.

• The trial uses a maximum tolerated dose strategy, refined through prior studies, to minimize treatment interruptions and optimize dosing.

• The same experienced team has conducted multiple HCM trials, ensuring methodological rigor and robust patient selection.

• Phase II data showed improvements in biomarkers, echo parameters, and patient-reported outcomes, with positive trends continuing in open-label extension.

• ACACIA-HCM results are expected in Q2, with initial disclosures likely qualitative, followed by detailed presentation at a major medical meeting.